BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
Nuvalent loses ground in the front line
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Exelixis claims a next-generation colorectal win
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
After Blueprint's takeover comes Cogent's big test
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
